product summary
Loading...
company name :
BioLegend
other brands :
Babco, Signet, Sternberger Monoclonals, Senetek, Covance
product type :
antibody
product name :
Brilliant Violet 570™ anti-mouse CD90.2 (Thy1.2)
catalog :
105329
quantity :
125 μL
price :
198 USD
clonality :
monoclonal
host :
rat
conjugate :
Brilliant Violet 570
clone name :
30-H12
reactivity :
mouse
application :
flow cytometry
more info or order :
citations: 6
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
Dyer K, Czapiga M, Foster B, Foster P, Kang E, Lappas C, et al. Eosinophils from lineage-ablated Delta dblGATA bone marrow progenitors: the dblGATA enhancer in the promoter of GATA-1 is not essential for differentiation ex vivo. J Immunol. 2007;179:1693-9 pubmed
|
product information
Antigen :
CD90.2
Apps. Abbrev. :
Flow Cytometry
Cat # :
105329
Clone :
30-H12
Item :
Brilliant Violet 570™ anti-mouse CD90.2 (Thy1.2)
Isotype :
Rat IgG2b, κ
Other Names :
Thy-1.2
Size :
125 μL
Price (USD) :
198 USD
Reactivity :
Mouse
Clonality :
Monoclonal
Host :
Rat
Conjugate/Tag/Label :
BV570
Immunogen :
Mouse thymus or spleen
Application Notes :
Additional reported applications (for the relevant formats) include: in vivo and in vitro depletion 1,2,7 , costimulation of CD3/TCR-mediated signal transduction 3,4 , and immunohistochemical staining 5 of acetone-fixed frozen sections. The 30-H12 antibody does not react with Thy-1.1 alloantigen of the AKR/J and PL strains. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301 101302) is recommended prior to immunofluorescent staining. The Ultra-LEAF purified antibody (Endotoxin 0.01 EU/ug, Azide-Free, 0.2 um filtered) is recommended for functional assays (Cat. Nos. 105351 105352).
more info or order :
company information

BioLegend
8999 BioLegend Way
San Diego, CA 92121
San Diego, CA 92121
customerserv@biolegend.com
https://www.biolegend.comheadquarters: USA
related products
browse more products
questions and comments